Company press releases
Released | Company | Title | Industry | Topic |
---|---|---|---|---|
09 Nov 2021 14:00 CET |
BERGENBIO | BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL DATA ON BEMCENTINIB IN STK11-POSITIVE NSCLC AT SITC ANNUAL MEETING 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
04 Nov 2021 15:11 CET |
BERGENBIO | BERGENBIO TO PRESENT UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
04 Nov 2021 07:00 CET |
BERGENBIO | BERGENBIO ASA: INVITATION TO THIRD QUARTER 2021 RESULTS PRESENTATION AND WEBCAST | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
04 Oct 2021 10:24 CEST |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Total number of voting rights and capital |
01 Oct 2021 15:20 CEST |
BERGENBIO | BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
30 Sep 2021 17:05 CEST |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options | 20103010 Biotechnology | Total number of voting rights and capital |
07 Sep 2021 19:21 CEST |
BERGENBIO | BERGENBIO COMPLETES RECRUITMENT OF PHASE II AML STUDY (BGBC003) | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
06 Sep 2021 09:36 CEST |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Total number of voting rights and capital |
31 Aug 2021 17:55 CEST |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options | 20103010 Biotechnology | Total number of voting rights and capital |
26 Aug 2021 17:25 CEST |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Total number of voting rights and capital |
23 Aug 2021 18:42 CEST |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options | 20103010 Biotechnology | Total number of voting rights and capital |
22 Aug 2021 20:30 CEST |
BERGENBIO | BERGENBIO ASA: LEADERSHIP CHANGE | 20103010 Biotechnology | Inside information |
22 Aug 2021 20:30 CEST |
BERGENBIO | BERGENBIO ASA: LEDERSKIFTE | 20103010 Biotechnology | Innsideinformasjon |
17 Aug 2021 07:00 CEST |
BERGENBIO | BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2021 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
06 Aug 2021 08:00 CEST |
BERGENBIO | BERGENBIO ANNOUNCES CHANGES TO SENIOR MANAGEMENT | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
04 Aug 2021 07:00 CEST |
BERGENBIO | BERGENBIO ASA: INVITATION TO PRESENTATION OF SECOND QUARTER AND HALF YEAR 2021 RESULTS | 20103010 Biotechnology | Non-regulatory press releases |
21 Jul 2021 07:00 CEST |
BERGENBIO | BERGENBIO COVID-19 DATA PRESENTED AT THE ANNUAL AMERICAN SOCIETY FOR VIROLOGY | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
12 Jul 2021 14:12 CEST |
BERGENBIO | BERGENBIO PRESENTS ENCOURAGING COMBINED DATA FOR BEMCENTINIB FROM TWO PHASE II COVID-19 STUDIES AT ECCMID | 20103010 Biotechnology | Inside information |
10 Jul 2021 13:00 CEST |
BERGENBIO | PRECLINICAL BEMCENTINIB AND TILVESTAMAB DATA PRESENTED AT EAU 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
29 Jun 2021 07:00 CEST |
BERGENBIO | BERGENBIO PRESENTING COVID-19 DATA IN LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
28 Jun 2021 07:00 CEST |
BERGENBIO | BERGENBIO TO PRESENT AT 4th ANNUAL NEXT GEN IMMUNO-ONCOLOGY VIRTUAL CONGRESS | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
16 Jun 2021 12:41 CEST |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Total number of voting rights and capital |
11 Jun 2021 20:24 CEST |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options and disclosure of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
11 Jun 2021 09:00 CEST |
BERGENBIO | BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING | 20103010 Biotechnology | Inside information |
11 Jun 2021 09:00 CEST |
BERGENBIO | BERGENBIO PRESENTERER LOVENDE OPPDATERTE PRELIMINÆRE DATA FRA FASE-II STUDIE I AML PASIENTER MED TILBAKEFALL PÅ VIRTUELT EHA SEMINAR | 20103010 Biotechnology | Innsideinformasjon |
10 Jun 2021 07:00 CEST |
BERGENBIO | BERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
08 Jun 2021 07:00 CEST |
BERGENBIO | BERGENBIO MOTTAR FDA FAST TRACK DESIGNATION FOR BEMCENTINIB/ANTI-PD-(L)1 KOMBINASJON I NSCLC | 20103010 Biotechnology | Innsideinformasjon |
08 Jun 2021 07:00 CEST |
BERGENBIO | BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 COMBINATION IN NSCLC | 20103010 Biotechnology | Inside information |
07 Jun 2021 07:00 CEST |
BERGENBIO | BERGENBIO TO PRESENT PRECLINICAL DATA ON TILVESTAMAB IN CHRONIC KIDNEY DISEASE AT ERA-EDTA VIRTUAL CONGRESS 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
04 Jun 2021 15:42 CEST |
BERGENBIO | BERGENBIO PRESENTS DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
25 May 2021 09:00 CEST |
BERGENBIO | BERGENBIO TO PRESENT AT ABGSC SEMINAR | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
20 May 2021 07:00 CEST |
BERGENBIO | BERGENBIO TO PRESENT DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |